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The growing number of patients who develop dia-
betes mellitus (DM) is a great concern for public health
care. Type 2 DM comprises 90% of all diabetic patients
worldwide, and is largely the result of excess body weight
and physical inactivity. Long term complications of DM
include microvascular damage and macrovascular inju-
ries. These complications reduce life expectancy and
quality of life, and significantly increase morbidity. Due
to the often masked symptoms of DM, the disease may be
diagnosed several years after onset when complications
have already occurred. Often, the prognosis of patients
with DM depends on the presence of cardiovascular dis-
ease. Coronary artery disease (CAD) is the leading cause
of morbidity and mortality in individuals with type 2
DM.1 The 10-year mortality rate in patients with known
CAD and diabetes exceeds 70%.2
Some studies suggest that the risk for future cardiac
death in patients with diabetes without known CAD is
similar to that in non-diabetic patients with overt clinical
CAD.2 In addition, early and late outcomes of diabetic
patients with acute coronary syndromes are worse than
those of their non-diabetic counterparts. To compound
the problem, myocardial ischemia is often asymptomatic
in patients with DM, and CAD is frequently in an
advanced state, when becoming clinically manifest.3,4
The previously described adverse clinical outcomes in
patients with diabetes underscores the need to develop
practical approaches to detect CAD in an early stage
before clinical symptoms occur. Thus, early detection
of CAD and myocardial ischemia appears to be important
to reduce morbidity and mortality from cardiovascular
disease in asymptomatic patients with type 2 DM. Iden-
tification of these asymptomatic diabetic patients might
be important to intervene early and to increase long term
survival. From a management perspective, patients with
high risk characteristics on testing for myocardial ische-
mia may benefit from coronary revascularization. With
regard to pharmacological therapy, the knowledge that a
patient with diabetes has CAD may indicate the need to
initiate or intensify pharmacological therapy with aspi-
rins, statins, and angiotensin converting enzyme (ACE)
inhibitors. Results from the BARI 2D trial showed no
significantly differences in survival rates as well as in
freedom from major cardiovascular events between
optimal medical therapy and revascularization.5 So, it
seems that testing for ischemia should be reserved for
selected individuals with a strong suspicion of high risk
CAD.
Single photon emission computed tomography
(SPECT) myocardial perfusion imaging (MPI) has been
used extensively in the detection of (silent) myocardial
ischemia in symptomatic as well as asymptomatic
patients with DM. Several studies in the literature suggest
a high prevalence of abnormal MPI in diabetic patients,
ranging from 37% to 62%.6-12 The same studies further-
more demonstrate, in a mean follow-up of 24-70 months,
a hard event rate of 3.6%-9.0% per year in diabetic
patients with abnormal MPI. Retrospective database
analysis reveals the same percentages of abnormal MPI
and hard event rates in symptomatic and asymptomatic
patients with diabetes.8-10,12-14 Prospective studies in
asymptomatic patients with diabetes show a lower prev-
alence of silent myocardial ischemia ranging from 6% to
22%.15-20 Differences in design and stress testing meth-
odology may explain these variations in prevalence. One
of these prospective studies is the DIAD trial.20 The les-
sons learned from this important trial has been
extensively described in this journal.21 The authors con-
cluded that routine screening of asymptomatic patients
with diabetes was not justified but they also speculated
that other imaging studies might provide additional
insights into models that might in combination with MPI
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identify subjects at high risk. Anand et al used a stepwise
protocol and proved in 510 asymptomatic patients with
type 2 DM that initial testing for coronary calcium by
electron beam computed tomography and SPECT MPI
can optimize the selection of patients who should undergo
stress MPI. During follow-up the majority of the events
occurred in patients with coronary artery calcium (CAC)
score of greater than 400.15
In this issue of the Journal, Peix et al22 report the
results of an interesting study. They investigated in 59
asymptomatic patients with type 2 DM the prevalence of
ischemia detected by SPECT MPI, and compared it to a
control group of 42 age and sex matched non-diabetic
volunteers, who also had risk factors for CAD. In
addition, they explored the relationship between silent
ischemia, endothelial dysfunction and the CAC score.
Endothelial dysfunction was tested by brachial artery
vasodilatation ultrasonography measurement, an indirect
measurement of coronary endothelial function. Standard
SPECT MPI and CAC score protocols were used. In 20
(34%) diabetic patients and in 7 (17%) controls perfu-
sion defects were observed. Although the majority of
diabetics with abnormal myocardial perfusion had
abnormal endothelial dysfunction, there was no signifi-
cant difference between the groups. Furthermore, as
suspected CAC score was significantly higher in the
diabetic group. The only variable that was associated
significantly with perfusion abnormalities was the
presence of diabetes. Although the number of patients is
small, this study is the first in which asymptomatic
diabetics are compared to matched controls with risk
factors for CAD, regarding detection of silent myocar-
dial ischemia. The incidence as well as the extent of
myocardial ischemia is within the range of previously
mentioned studies. Even though the majority of the
patients had extensive number of risk factors for CAD,
all were able to perform an exercise test, suggesting a
relative ‘‘healthy’’ diabetic population without serious
complications such as peripheral artery disease and
diabetic neuropathy. The authors explored the interre-
lationship between myocardial perfusion abnormalities,
CAC score and endothelial dysfunction. This relation-
ship is interesting because it may explain the
discrepancy between the presence of myocardial perfu-
sion defects and the absence of obstructive epicardial
CAD. While among diabetics, 69% of the patients with
abnormal perfusion had endothelial dysfunction, only a
small number of diabetics with perfusion abnormalities
showed abnormal CAC score. Accordingly, endothelial
dysfunction may have a greater impact on myocardial
perfusion than the extent of diffuse atherosclerosis. This
condition most likely represents an early stage of vas-
cular disease amenable to treatment, and intensification
of antiatherogenic therapy seems to be indicated.
Certainly, the DIAD trial showed that intense treatment
with statins, aspirin, and ACE inhibitors reduced
inducible ischemia in 79% of asymptomatic diabetic
patients.23 In this respect it is remarkable to see the low
number of patients in the current study of Peix et al who
were on these medications.
Considering that in DM, abnormal myocardial per-
fusion is often observed in the absence of epicardial
obstructive CAD, one can wonder whether SPECT MPI
in asymptomatic patients with type 2 DM should be
accompanied by CAC scoring. Possibly multislice com-
puted tomography coronary angiography could have
incremental value in asymptomatic patients with diabetes
with abnormal myocardial perfusion. MSCT can differ-
entiate between obstructive epicardial CAD and
endothelial dysfunction as the cause of myocardial per-
fusion abnormalities. However, combining these two
cardiac imaging modalities increases health care costs
and radiation exposure. Given the increasing prevalence
of diabetes it is important first to optimize and intensify
pharmacological therapy. Secondly, close and careful
follow-up of these patients might reveal that asymptom-
atic diabetic patients often have atypical angina
complaints or dyspnea, and can selectively be referred for
further clinical testing of myocardial ischemia. More-
over, is testing with different algorithms still needed to
better identify asymptomatic patients with type 2 DM at
higher risk?
Although recent ACCF/AHA guidelines suggest
that peripheral arterial flow-mediated dilation is not
recommended in asymptomatic patients, stress MPI may
be considered in asymptomatic patients with diabetes.24
Conversely, a recent post hoc analysis of the DIAD
study showed that patients with intermediate/high risk
baseline risk had a low annual cardiac event rate, which
was not altered by routine screening for inducible
ischemia.25 The current prospective multicenter study is
still in progress and by increasing the number of patients
it may give answer to the question if we still need to
combine different imaging modalities and surrogate
markers to identify the high risk asymptomatic patient
with type 2 DM.
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